Related Experiment Video
Updated: May 5, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Human metapneumovirus
Jennifer E Schuster1, John V Williams
1Vanderbilt University School of Medicine, Nashville, Tennessee.
Abstract:
On the basis of strong research evidence and consensus, (1) (2) (3) (4) human metapneumovirus is a leading cause of upper and lower respiratory tract infections in children. On the basis of research evidence and consensus, (3) (5) (6) (7) the clinical features of MPV-associated disease are similar to those of RSV. MPV is an important cause of asthma exacerbations, bronchiolitis, and pneumonia. Bacterial superinfection can occur.On the basis of research evidence and consensus, (2) (3) (8) the mean age of infection is 6 to 12 months, and nearly all school-age children are seropositive. However, infection can recur, likely in part due to impaired CD8+ T-cell response. On the basis of research evidence and consensus, (9) (10) (11) morbidity and mortality are the highest in patients who are premature, are immunosuppressed, or have underlying cardiopulmonary abnormalities. On the basis of research evidence and consensus, (2) commercially available diagnostic tests exist, and reverse transcriptase–PCR is the most commonly used. On the basis of consensus, because of a lack of relevant clinical studies, recombinant virus vaccines and monoclonal antibodies may be useful as prophylactics or therapeutics. (10)
Insights
Human metapneumovirus (MPV) causes significant respiratory infections in children, with symptoms resembling RSV. Early diagnosis and potential prophylactic treatments are crucial for high-risk infants.
Area of Science:
- Pediatric Infectious Diseases
- Virology
- Immunology
Background:
- Human metapneumovirus (MPV) is a significant pathogen responsible for a substantial burden of pediatric respiratory illnesses.
- Clinical manifestations of MPV infection often mimic those of Respiratory Syncytial Virus (RSV), complicating diagnosis.
Observation:
- MPV is a primary cause of both upper and lower respiratory tract infections in children, including asthma exacerbations, bronchiolitis, and pneumonia.
- Bacterial superinfections can complicate MPV disease.
- The typical age of first infection is between 6 to 12 months, with near-universal seropositivity by school age, though reinfection can occur.
Findings:
- Morbidity and mortality associated with MPV are disproportionately higher in premature infants, immunocompromised individuals, and those with pre-existing cardiopulmonary conditions.
- Commercially available diagnostic tests, particularly reverse transcriptase–PCR (RT-PCR), are widely used for MPV detection.
Implications:
- The lack of extensive clinical studies necessitates further research into the efficacy of prophylactic and therapeutic interventions.
- Recombinant virus vaccines and monoclonal antibodies show potential for preventing or treating MPV infections, especially in vulnerable populations.
More Related Videos
09:01An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
Atypical Pneumonia
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Cytomegalovirus Disease
Human Virome